FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035051761> ?p ?o ?g. }

• W2035051761 endingPage "1479" @default.
• W2035051761 startingPage "1475" @default.
• W2035051761 abstract "Preclinical data suggest that the anti-tumour activity of capecitabine is enhanced by taxanes and mitomycin C through up-regulation of thymidine phosphorylase (TP). Here, we studied safety and efficacy of the combination of capecitabine with docetaxel and mitomycin C. Two dose levels (DL) were investigated: capecitabine 1000 mg m−2 b.i.d. on days 1–14, docetaxel 40 mg m−2 i.v. day 1, mitomycin C 4 or 6 mg m−2 i.v. day 1 (DL I or II). Cycles were repeated every 3 weeks. The primary aim was to determine the dose-limiting toxicities (DLT) during the first two treatment cycles and the maximum tolerated dose (MTD). A total of 46 patients (pts) refractory to standard therapies were enrolled, of whom the majority had gastrointestinal tumours (n=40). 14 pts had received ⩾3 lines of prior chemotherapy. At DL I, one out of six pts experienced DLT. At DL II, two out of six pts had DLT (mucositis grade 3). Thus, DL I was determined as MTD. Among a total of 37 pts treated on DL I the following toxicities were observed during cycles 1 and 2 (number of patients with grade 1/2/3/4 toxicity; NCI-CTC v. 3.0): anaemia 10/8/3/0, leucocytopenia 4/11/1/2, thrombocytopenia 0/1/2/0, diarrhoea 8/1/2/0, stomatitis/mucositis 3/3/1/0, nausea/vomiting 10/2/0/0, and hand-foot skin reaction 5/1/1/0. Of 30 pts who received at least two treatment cycles nine achieved complete or partial remissions, six pts achieved minor remissions, and seven pts had stable disease (tumour control rate 73%). Of note, four out of 10 patients with pancreatic cancer had partial remissions. In conclusion, capecitabine can safely be combined with docetaxel (40 mg m−2) and mitomycin C (4 mg m−2). The established regimen was well tolerated and the preliminary efficacy data in this heavily pre-treated patients population appears to be promising." @default.
• W2035051761 created "2016-06-24" @default.
• W2035051761 creator A5018229437 @default.
• W2035051761 creator A5035964802 @default.
• W2035051761 creator A5038048953 @default.
• W2035051761 creator A5040836871 @default.
• W2035051761 creator A5054698965 @default.
• W2035051761 creator A5055281501 @default.
• W2035051761 creator A5062937551 @default.
• W2035051761 creator A5075238372 @default.
• W2035051761 date "2007-11-13" @default.
• W2035051761 modified "2023-10-10" @default.
• W2035051761 title "Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial" @default.
• W2035051761 cites W1525210877 @default.
• W2035051761 cites W1966004974 @default.
• W2035051761 cites W1971345605 @default.
• W2035051761 cites W1973948284 @default.
• W2035051761 cites W1993389431 @default.
• W2035051761 cites W2000918206 @default.
• W2035051761 cites W2007742741 @default.
• W2035051761 cites W2019068319 @default.
• W2035051761 cites W2059122027 @default.
• W2035051761 cites W2060029165 @default.
• W2035051761 cites W2065280992 @default.
• W2035051761 cites W2090617085 @default.
• W2035051761 cites W2092878111 @default.
• W2035051761 cites W2096122707 @default.
• W2035051761 cites W2097121246 @default.
• W2035051761 cites W2101703182 @default.
• W2035051761 cites W2105160417 @default.
• W2035051761 cites W2110108978 @default.
• W2035051761 cites W2131770017 @default.
• W2035051761 cites W2137194656 @default.
• W2035051761 cites W2138577761 @default.
• W2035051761 cites W2139186978 @default.
• W2035051761 cites W2139947970 @default.
• W2035051761 cites W2162851031 @default.
• W2035051761 cites W2169764884 @default.
• W2035051761 cites W2407982120 @default.
• W2035051761 cites W2469661112 @default.
• W2035051761 cites W2543373661 @default.
• W2035051761 cites W4293241248 @default.
• W2035051761 doi "https://doi.org/10.1038/sj.bjc.6604067" @default.
• W2035051761 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2360249" @default.
• W2035051761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18000507" @default.
• W2035051761 hasPublicationYear "2007" @default.
• W2035051761 type Work @default.
• W2035051761 sameAs 2035051761 @default.
• W2035051761 citedByCount "2" @default.
• W2035051761 crossrefType "journal-article" @default.
• W2035051761 hasAuthorship W2035051761A5018229437 @default.
• W2035051761 hasAuthorship W2035051761A5035964802 @default.
• W2035051761 hasAuthorship W2035051761A5038048953 @default.
• W2035051761 hasAuthorship W2035051761A5040836871 @default.
• W2035051761 hasAuthorship W2035051761A5054698965 @default.
• W2035051761 hasAuthorship W2035051761A5055281501 @default.
• W2035051761 hasAuthorship W2035051761A5062937551 @default.
• W2035051761 hasAuthorship W2035051761A5075238372 @default.
• W2035051761 hasBestOaLocation W20350517611 @default.
• W2035051761 hasConcept C121332964 @default.
• W2035051761 hasConcept C121608353 @default.
• W2035051761 hasConcept C126322002 @default.
• W2035051761 hasConcept C141071460 @default.
• W2035051761 hasConcept C142424586 @default.
• W2035051761 hasConcept C2776694085 @default.
• W2035051761 hasConcept C2777909004 @default.
• W2035051761 hasConcept C2778496288 @default.
• W2035051761 hasConcept C2779051857 @default.
• W2035051761 hasConcept C2779338040 @default.
• W2035051761 hasConcept C2780580376 @default.
• W2035051761 hasConcept C2780852908 @default.
• W2035051761 hasConcept C2781190966 @default.
• W2035051761 hasConcept C526805850 @default.
• W2035051761 hasConcept C71924100 @default.
• W2035051761 hasConcept C87355193 @default.
• W2035051761 hasConcept C90924648 @default.
• W2035051761 hasConceptScore W2035051761C121332964 @default.
• W2035051761 hasConceptScore W2035051761C121608353 @default.
• W2035051761 hasConceptScore W2035051761C126322002 @default.
• W2035051761 hasConceptScore W2035051761C141071460 @default.
• W2035051761 hasConceptScore W2035051761C142424586 @default.
• W2035051761 hasConceptScore W2035051761C2776694085 @default.
• W2035051761 hasConceptScore W2035051761C2777909004 @default.
• W2035051761 hasConceptScore W2035051761C2778496288 @default.
• W2035051761 hasConceptScore W2035051761C2779051857 @default.
• W2035051761 hasConceptScore W2035051761C2779338040 @default.
• W2035051761 hasConceptScore W2035051761C2780580376 @default.
• W2035051761 hasConceptScore W2035051761C2780852908 @default.
• W2035051761 hasConceptScore W2035051761C2781190966 @default.
• W2035051761 hasConceptScore W2035051761C526805850 @default.
• W2035051761 hasConceptScore W2035051761C71924100 @default.
• W2035051761 hasConceptScore W2035051761C87355193 @default.
• W2035051761 hasConceptScore W2035051761C90924648 @default.
• W2035051761 hasIssue "11" @default.
• W2035051761 hasLocation W20350517611 @default.
• W2035051761 hasLocation W20350517612 @default.
• W2035051761 hasLocation W20350517613 @default.
• W2035051761 hasLocation W20350517614 @default.

• next